Although there is limited information on the mechanism of this grading phenomenon, a 2020 study suggested that as immunotherapy becomes more established as a standard treatment for RCC, the dysfunction of CD4 and CD8 T cells infiltrating tumor tissue is more pronounced in higher-grade tumors20. Here, CD8A is linked to renal cell carcinoma.